FDA Intensifies Crackdown on Celebrity and Weight-Loss Drug Ads
TL;DR
The FDA has issued multiple warning letters to pharmaceutical companies, including Eli Lilly and Novo Nordisk, for misleading drug advertisements across various media, emphasizing concerns over safety disclosures and the portrayal of drugs in a way that may mislead consumers, as part of a broader crackdown on deceptive marketing practices in the industry.
Topics:businesshealth#drug-advertising#fda#health#misleading-ads#pharmaceutical-companies#regulation
- FDA Letters Flag Oprah Video, Morgan Freeman Ad in Crackdown Bloomberg.com
- FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz AP News
- FDA—After Trump Order—Warns Pharma Giants Over Weight-Loss Ads Forbes
- U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims Reuters
- AstraZeneca TV spot for at-home FluMist lands in FDA crosshairs as DTC ad crackdown ramps up Fierce Pharma
Want the full story? Read the original reporting
Read on Bloomberg.com